FIG 6.
Sph3h prophylaxis enhances posaconazole activity in a neutropenic mouse model of pulmonary invasive aspergillosis. Neutropenic mice were intratracheally infected with 5 × 103 wild-type A. fumigatus conidia coadministered with or without 500 μg Sph3h and then treated as indicated with 2.5 mg/kg posaconazole every 12 h for 2 days. Pulmonary fungal burden was determined by pulmonary galactomannan quantification. Bars represent 3 independent experiments with ≥17 mice per group. A significant difference is indicated (*, P = 0.0063) relative to all groups as determined by Kruskal-Wallis test with Dunn’s multiple-comparison test. Posa, posaconazole.